Back to results
US 10,590,488 B2Granted
Recurrent gene fusions in cutaneous CD30-positive lymphoproliferative disorders
AssigneeThe Regents of the University of Michigan
InventorsKojo Elenitoba-Johnson, Mark J. Kiel, Delphine Rolland, Bryan L. Betz, Nathanael G. Bailey, Thirunavukkarasu Velusamy, Megan Lim
Life of this patent
Estimating the term…
Abstract
Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions (e.g., recurrent translocations involving TYK2) as diagnostic markers and clinical targets for cutaneous CD30-positive lymphoproliferative disorders (e.g., lymphomatoid papulosis; primary cutaneous anaplastic large cell lymphoma).
Claims1
A method, comprising
- a) obtaining a nucleic acid sample from a subject suspected of having or having a neoplastic disorder, wherein the neoplastic disorder is a cutaneous CD30-positive lymphoproliferative disorder, wherein the cutaneous CD30-positive lymphoproliferative disorder is lymphomatoid papulosis and/or primary cutaneous anaplastic large cell lymphoma;
- b) amplifying the obtained nucleic acid sample with a pair of primers that amplify a fusion junction of a NPM1-TYK2 gene fusion having the sequence of SEQ ID NO:
- 89;
- and
- c) measuring amplification of SEQ ID NO:
- 89 by Q-PCR.
3 more elements
Dependencies are inferred from the claim text.